Project Grant R43HL169010
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $583,718 Project Grant to Berendo Scientific LLC under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize and evaluate the SLEEPFLEX head and neck exercise program for the treatment of mild to moderate obstructive sleep apnea (OSA). The project aims to develop a focused, effective, safe, and non-invasive head and neck exercise program delivered via a smartphone app to increase the strength and endurance of key...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $818,279 to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on improving the subtyping and characterization of obstructive sleep apnea (OSA). The project will leverage data from existing research cohorts and a clinical biobank to quantify the reproducibility of OSA severity markers and derive physiologically...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $305,746 Project Grant under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) to Soliish, Inc. The award aims to develop a novel digital platform that uses deep learning to deliver a cost-effective, non-invasive, and user-friendly solution for early detection of obstructive sleep apnea (OSA). The solution, called OSANet, leverages analysis of oral cavity images to predict OSA risk and support...
- The U.S. National Heart Lung and Blood Institute awarded a $316,609 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Remastered Sleep LLC for the development of a "Novel Myofunctional Nipple to Prevent Obstructive Sleep Apnea in Infants." The project aims to address the clear unmet need for a non-invasive, first-line treatment and preventive measure for obstructive sleep apnea (OSA) in infants, which can have detrimental long-term health impacts...
- This federal Project Grant award of $449,861 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support a 24-month clinical observational feasibility study on dental practitioners' oral appliance therapy (OAT) titration methods and outcomes for patients with obstructive sleep apnea (OSA). The study will recruit 10 dental practitioners and 60 OSA patients (6 per practitioner) to examine practitioners'...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to elucidate the complex relationship between obstructive sleep apnea (OSA) and cardiovascular disease (CVD). The $1,296,660 award supports a 24-month research project that will employ a "bed to bench" approach integrating clinical, computational, and in vitro techniques. Key objectives include developing and validating a mathematical model to quantify...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will validate a new, minimally invasive cervical surgical approach to phrenic nerve stimulation for the treatment of central sleep apnea (CSA). The $982,086 project, awarded to Coridea, LLC, a medical technology firm in New York, aims to develop a simplified procedure that can be performed in an outpatient setting by ENT surgeons, as the current commercially...
- This $782,473 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to improve understanding of the pathogenesis of sleep apnea using novel imaging techniques during sleep. The project aims to characterize the site and pattern of airway collapse as well as how upper airway anatomy mediates this collapse, which could provide new insights to guide optimal therapies, particularly for patients who cannot tolerate...
- This Project Grant award of $371,021 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a continuous respiratory monitoring platform to better classify apnea of prematurity (AOP) in premature newborns. The primary products to be delivered are: 1) a multimodal system and machine learning model to accurately detect and classify the major types of AOP (central, obstructive, and mixed); and 2) an optimized prototype system...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,415,112 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nebraska Medical Center (UNMC) to evaluate a telehealth-delivered adaptive intervention for improving continuous positive airway pressure (CPAP) therapy adherence and health outcomes in adults with obstructive sleep apnea (OSA). The project aims to: 1) compare effects of motivational enhancement, device support, and...
A MULTI-SENSOR CATHETER FOR DIAGNOSING OBSTRUCTIVE SLEEP APNEA - PROJECT SUMMARY FEW MEDICAL DISORDERS HAVE A LARGER PUBLIC HEALTH IMPACT THAN OBSTRUCTIVE SLEEP APNEA (OSA). OSA AFFECTS MORE THAN 20 MILLION PEOPLE IN THE US ALONE, AND WHEN UNTREATED, IT IS ASSOCIATED WITH SIGNIFICANT COMORBIDITIES AND MORTALITY. CURRENT DIAGNOSTIC TESTS FOR OSA, HOWEVER, ARE EXPENSIVE, INCONVENIENT, AND LARGELY INEFFECTIVE. OVERNIGHT IN-FACILITY SLEEP STUDIES, ALSO KNOWN AS POLYSOMNOGRAPHY (PSG), SHOW LOW PATIENT COMPLIANCE AND LIMITED SENSITIVITY AND SPECIFICITY, LARGELY DUE TO THE ANATOMICAL COMPLEXITY OF OSA. DRUG-INDUCED SLEEP ENDOSCOPY (DISE) CAN PROVIDE ADDITIONAL INFORMATION ON THE TYPE AND LOCATION OF OBSTRUCTION, BUT IT REQUIRES DIRECT INVOLVEMENT OF A TRAINED OTOLARYNGOLOGIST AND ANESTHESIA PROFESSIONAL. FURTHERMORE, ITS RELIABILITY IS LIMITED DUE TO THE SUBJECTIVE NATURE OF THE FINDINGS. IN SHORT, A SAFE, PORTABLE, AND EFFICIENT INSTRUMENT FOR RAPID CHARACTERIZATION OF OBSTRUCTIVE AIRWAY PHYSIOLOGY WOULD FIND WIDE USE IN THE ASSESSMENT OF PATIENTS WITH SUSPECTED OBSTRUCTIVE SLEEP APNEA. THIS SYSTEM WOULD BENEFIT MILLIONS OF PATIENTS BY PROVIDING CRITICAL INFORMATION TO AID IN THE DETERMINATION OF THE BEST THERAPY FOR OSA IN A PARTICULAR PATIENT. WE BELIEVE THAT THE MULTI-SENSOR CATHETER SYSTEM WE ARE PROPOSING CAN SERVE THIS ROLE. BOLD TYPE IS DEVELOPING THE "SMARTCATHETER" SYSTEM, A WIRELESS, CLOUD-CONNECTED, MULTI-SENSOR CATHETER AND TABLET APP DESIGNED TO PROVIDE RAPID EVALUATION OF UPPER AIRWAY OBSTRUCTION TO DIAGNOSE OBSTRUCTIVE SLEEP APNEA (OSA). WE HYPOTHESIZE THAT: (1) AN INNOVATIVE SYSTEM FOR MEASURING AND ANALYZING ACOUSTIC AND PRESSURE ALONG THE UPPER AIRWAY CAN BE DEVELOPED; (2) THAT COMBINED DATA FROM ACOUSTIC AND PRESSURE SENSORS WILL BE SENSITIVE TO OBSTRUCTION PRESENCE, LOCATION, TYPE, AND DEGREE; AND (3) THAT ALGORITHMS CAN BE DEVELOPED TO CONVERT RAW ACOUSTIC AND PRESSURE DATA INTO SUMMARY METRICS THAT FACILITATE THE DIAGNOSIS OF OBSTRUCTIVE SLEEP APNEA. WE PROPOSE THE FOLLOWING SPECIFIC AIMS: IN AIM 1, WE WILL DEVELOP A SMARTCATHETER SYSTEM COMPOSED OF A WIRELESS, NASO-ESOPHAGEAL MULTI-SENSOR CATHETER TO RECORD DYNAMIC ACOUSTIC PRESSURE AND STATIC PRESSURE ALONG THE UPPER AIRWAY, AND A TABLET APP TO COMMUNICATES WIRELESSLY WITH THE CATHETER, PERFORM ALGORITHMS ON ACOUSTIC AND PRESSURE WAVEFORMS, PROVIDE VISUAL FEEDBACK TO THE USER, AND TRANSFER DATA TO A DATABASE FOR STORAGE AND ANALYSIS. IN AIM 2, WE WILL DEVELOP PRELIMINARY DIAGNOSTIC ALGORITHMS CAPABLE OF DETECTING THE PRESENCE, LOCATION, TYPE, AND DEGREE OF OBSTRUCTION IN AN AIRWAY SIMULATOR. AND IN AIM 3, WE WILL CONDUCT A LIMITED PROOF-OF-CONCEPT HUMAN STUDY USING THE SYSTEM DEVELOPED IN AIM 1 WITH 5 HEALTHY CONTROLS AND 5 OSA PATIENTS TO GATHER PRELIMINARY HUMAN DATA AND EVALUATE ACOUSTIC AND PRESSURE DIFFERENCES BETWEEN THE TWO GROUPS. UPON SUCCESSFUL COMPLETION OF THESE THREE AIMS, WE WILL BE WELL POISED TO PURSUE A PHASE 2 SBIR PROJECT GEARED TOWARD DEVELOPING A COMMERCIALIZATION READY SMARTCATHETER SYSTEM AND VALIDATING IT IN A MULTI-SITE STUDY COMPARING PERFORMANCE AGAINST PSG AND DISE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 10/30/24 | ||
| Not listed | $299.7k | 6/1/23 |